Methotrexate treatment in patients with adult onset Still's disease - Retrospective study of 13 Japanese cases

Takao Fujii, Masashi Akizuki, Hideto Kameda, Mami Matsumura, Michito Hirakata, Tadashi Yoshida, Taeko Shinozawa, Tsuneyo Mimori

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Objective: To evaluate methotrexate treatment in patients with active adult onset Still's disease (AOSD). Methods: Methotrexate was initially given as a single weekly oral dose of 5 mg and adjusted individually afterwards in 13 patients with active AOSD. Symptoms and laboratory findings were investigated. Results: Signs of AOSD activity disappeared (remission) in eight patients between 3 and 16 weeks after starting methotrexate. In these patients, significant improvements in C reactive protein, erythrocyte sedimentation rate, white blood count, and serum ferritin were observed at 8, 12, 14, and 16 weeks after starting methotrexate, respectively. In six of these eight patients, steroids or non-steroidal anti-inflammatory drugs could be reduced or discontinued. In four patients methotrexate was not effective despite 12 or 16 weeks of treatment, and one patient discontinued treatment after 2 weeks because of severe nausea. Five patients suffered from adverse reactions, including acute interstitial pneumonia (one patient) and liver toxicity (two patients). Five out of eight patients successfully treated with methotrexate were HLA-DR4 positive (four homozygotes), and all the unsuccessfully treated patients were DR2 positive. Conclusions: Methotrexate is useful for controlling disease activity in AOSD, not only for refractory patients but also for patients who have never taken steroids or for those with steroid associated toxicity. However, serious adverse reactions can occur, as with rheumatoid arthritis. It is important to determine the critical factors, such as the immunogenetic background, that are associated with response to methotrexate treatment.

Original languageEnglish
Pages (from-to)144-148
Number of pages5
JournalAnnals of the Rheumatic Diseases
Volume56
Issue number2
Publication statusPublished - 1997

Fingerprint

Adult-Onset Still's Disease
Methotrexate
Retrospective Studies
Steroids
Therapeutics
Toxicity
Patient treatment
HLA-DR4 Antigen
Ferritins
Sedimentation
Liver
Refractory materials
C-Reactive Protein
Blood
Anti-Inflammatory Agents
Immunogenetics
Blood Sedimentation
Interstitial Lung Diseases
Homozygote

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Methotrexate treatment in patients with adult onset Still's disease - Retrospective study of 13 Japanese cases. / Fujii, Takao; Akizuki, Masashi; Kameda, Hideto; Matsumura, Mami; Hirakata, Michito; Yoshida, Tadashi; Shinozawa, Taeko; Mimori, Tsuneyo.

In: Annals of the Rheumatic Diseases, Vol. 56, No. 2, 1997, p. 144-148.

Research output: Contribution to journalArticle

Fujii, T, Akizuki, M, Kameda, H, Matsumura, M, Hirakata, M, Yoshida, T, Shinozawa, T & Mimori, T 1997, 'Methotrexate treatment in patients with adult onset Still's disease - Retrospective study of 13 Japanese cases', Annals of the Rheumatic Diseases, vol. 56, no. 2, pp. 144-148.
Fujii, Takao ; Akizuki, Masashi ; Kameda, Hideto ; Matsumura, Mami ; Hirakata, Michito ; Yoshida, Tadashi ; Shinozawa, Taeko ; Mimori, Tsuneyo. / Methotrexate treatment in patients with adult onset Still's disease - Retrospective study of 13 Japanese cases. In: Annals of the Rheumatic Diseases. 1997 ; Vol. 56, No. 2. pp. 144-148.
@article{67ec7d46869b472a83907999aeb035ae,
title = "Methotrexate treatment in patients with adult onset Still's disease - Retrospective study of 13 Japanese cases",
abstract = "Objective: To evaluate methotrexate treatment in patients with active adult onset Still's disease (AOSD). Methods: Methotrexate was initially given as a single weekly oral dose of 5 mg and adjusted individually afterwards in 13 patients with active AOSD. Symptoms and laboratory findings were investigated. Results: Signs of AOSD activity disappeared (remission) in eight patients between 3 and 16 weeks after starting methotrexate. In these patients, significant improvements in C reactive protein, erythrocyte sedimentation rate, white blood count, and serum ferritin were observed at 8, 12, 14, and 16 weeks after starting methotrexate, respectively. In six of these eight patients, steroids or non-steroidal anti-inflammatory drugs could be reduced or discontinued. In four patients methotrexate was not effective despite 12 or 16 weeks of treatment, and one patient discontinued treatment after 2 weeks because of severe nausea. Five patients suffered from adverse reactions, including acute interstitial pneumonia (one patient) and liver toxicity (two patients). Five out of eight patients successfully treated with methotrexate were HLA-DR4 positive (four homozygotes), and all the unsuccessfully treated patients were DR2 positive. Conclusions: Methotrexate is useful for controlling disease activity in AOSD, not only for refractory patients but also for patients who have never taken steroids or for those with steroid associated toxicity. However, serious adverse reactions can occur, as with rheumatoid arthritis. It is important to determine the critical factors, such as the immunogenetic background, that are associated with response to methotrexate treatment.",
author = "Takao Fujii and Masashi Akizuki and Hideto Kameda and Mami Matsumura and Michito Hirakata and Tadashi Yoshida and Taeko Shinozawa and Tsuneyo Mimori",
year = "1997",
language = "English",
volume = "56",
pages = "144--148",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "2",

}

TY - JOUR

T1 - Methotrexate treatment in patients with adult onset Still's disease - Retrospective study of 13 Japanese cases

AU - Fujii, Takao

AU - Akizuki, Masashi

AU - Kameda, Hideto

AU - Matsumura, Mami

AU - Hirakata, Michito

AU - Yoshida, Tadashi

AU - Shinozawa, Taeko

AU - Mimori, Tsuneyo

PY - 1997

Y1 - 1997

N2 - Objective: To evaluate methotrexate treatment in patients with active adult onset Still's disease (AOSD). Methods: Methotrexate was initially given as a single weekly oral dose of 5 mg and adjusted individually afterwards in 13 patients with active AOSD. Symptoms and laboratory findings were investigated. Results: Signs of AOSD activity disappeared (remission) in eight patients between 3 and 16 weeks after starting methotrexate. In these patients, significant improvements in C reactive protein, erythrocyte sedimentation rate, white blood count, and serum ferritin were observed at 8, 12, 14, and 16 weeks after starting methotrexate, respectively. In six of these eight patients, steroids or non-steroidal anti-inflammatory drugs could be reduced or discontinued. In four patients methotrexate was not effective despite 12 or 16 weeks of treatment, and one patient discontinued treatment after 2 weeks because of severe nausea. Five patients suffered from adverse reactions, including acute interstitial pneumonia (one patient) and liver toxicity (two patients). Five out of eight patients successfully treated with methotrexate were HLA-DR4 positive (four homozygotes), and all the unsuccessfully treated patients were DR2 positive. Conclusions: Methotrexate is useful for controlling disease activity in AOSD, not only for refractory patients but also for patients who have never taken steroids or for those with steroid associated toxicity. However, serious adverse reactions can occur, as with rheumatoid arthritis. It is important to determine the critical factors, such as the immunogenetic background, that are associated with response to methotrexate treatment.

AB - Objective: To evaluate methotrexate treatment in patients with active adult onset Still's disease (AOSD). Methods: Methotrexate was initially given as a single weekly oral dose of 5 mg and adjusted individually afterwards in 13 patients with active AOSD. Symptoms and laboratory findings were investigated. Results: Signs of AOSD activity disappeared (remission) in eight patients between 3 and 16 weeks after starting methotrexate. In these patients, significant improvements in C reactive protein, erythrocyte sedimentation rate, white blood count, and serum ferritin were observed at 8, 12, 14, and 16 weeks after starting methotrexate, respectively. In six of these eight patients, steroids or non-steroidal anti-inflammatory drugs could be reduced or discontinued. In four patients methotrexate was not effective despite 12 or 16 weeks of treatment, and one patient discontinued treatment after 2 weeks because of severe nausea. Five patients suffered from adverse reactions, including acute interstitial pneumonia (one patient) and liver toxicity (two patients). Five out of eight patients successfully treated with methotrexate were HLA-DR4 positive (four homozygotes), and all the unsuccessfully treated patients were DR2 positive. Conclusions: Methotrexate is useful for controlling disease activity in AOSD, not only for refractory patients but also for patients who have never taken steroids or for those with steroid associated toxicity. However, serious adverse reactions can occur, as with rheumatoid arthritis. It is important to determine the critical factors, such as the immunogenetic background, that are associated with response to methotrexate treatment.

UR - http://www.scopus.com/inward/record.url?scp=0030890163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030890163&partnerID=8YFLogxK

M3 - Article

C2 - 9068291

AN - SCOPUS:0030890163

VL - 56

SP - 144

EP - 148

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 2

ER -